JAMA Network
About The Study: In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice.
Corresponding Author: To contact the corresponding author, Marianna Fontana, MD, PhD, email [email protected].
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4578)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
